/
LNTH
$101.41+$0.03 (+0.03%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$6.6B
65M shares
52-week range
$47.25 – $111.86
84% from low
Sector
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Exchange
NASDAQ
CS
Change+$74.23
Lantheus Holdings, Inc
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.
www.lantheus.com- Employees
- 1,193
- IPO / List date
- Jun 25, 2015
- HQ
- NORTH BILLERICA, MA
Held by traders on TradeandTell
No one on the platform currently holds LNTH.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 77,182 | $5.9M |
| Bridgewater Associatesas of 2026-03-31 | 43,720 | $3.3M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded LNTH yet.
